Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced today that it will present updated long-term efficacy and safety results from the locally advanced cutaneous squamous cell carcinoma (laCSCC) and metastatic CSCC (mCSCC) expansion cohorts from the pivotal CK-301-101 trial of UNLOXCYT® (cosibelimab-ipdl) at the European Society for Medical Oncology (ESMO) Congress on October 24, 2026 in Madrid, Spain.

Key Findings from ESMO 2026 Presentation

The ESMO abstract expands the pivotal analysis to 205 patients across three advanced CSCC cohorts using centrally-reviewed data. Notably, 34% of patients with locally advanced disease achieved a complete response (CR), while 17%-21% of metastatic patients achieved a CR. The tolerability profile remained consistent with earlier analyses, with a low level of high-grade immune-related adverse events (irAEs).

Clinical Implications

These results underscore the potential for cosibelimab to deliver clinically meaningful and durable benefit for patients with advanced CSCC. The consistent benefit-risk profile over time, with maintained response rates and increasing proportion of complete responses, highlights the promising efficacy of UNLOXCYT® in treating advanced skin cancers.

Ahmad Naim, MD, Senior Vice President, North American Chief Medical Officer, Sun Pharma, emphasized, ‘These findings of improvements in clinical response and consistent safety profile of low irAEs over time support the unmet need for patients with advanced CSCC. And reflects Sun Pharma’s continued commitment to advancing care and providing innovative treatment options that address the needs of patients with difficult-to-treat skin cancers.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun falls 9.0% over three months and has not found a floor yet. The PEG reaches 3.29. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 38% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.

Dr. Reddy’s Laboratories Limited (DRREDDY) showcased robust financial performance for Q2FY27, as per consolidated financial statements under IFRS. The company reported a revenue of ₹8,671 Cr, marking a 1.5% year-on-year growth. The EBITDA margin stood at 20.6%, reflecting consistent double-digit base business growth. The company’s progress across strategic priorities highlights its commitment to innovation and market expansion.

Financial Highlights

The financial highlights for Q2FY27 include a reported EBITDA of ₹1,783 Cr, a 24% year-on-year increase. The PBT reached ₹1,228 Cr, up 33% YoY, and PAT stood at ₹925 Cr, with a 36% YoY growth. Notably, the RoCE was annualized at 9.5%, and the net cash surplus stood at ₹2,502 Cr.

Strategic Initiatives

Dr. Reddy’s Laboratories Limited has made significant strides in its strategic initiatives. The company partnered with Takeda for India’s first CDSCO approved dengue vaccine, QDENGA, set to launch in private markets in H1 2027. Additionally, collaborations with Gilead Sciences and GARDP Foundation have expanded its global footprint.

The company also secured approval for rituximab biosimilar from the USFDA and launched nivolumab biosimilar in India. Furthermore, generic semaglutide has been approved in 10 countries across Latin America, Africa & the Middle East, as well as Canada & India.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.

Lupin Limited (LUPIN) announced the appointment of Brian Savage as President, Chief Legal Officer. Brian will lead Lupin’s global Legal, Compliance, and Intellectual Property Management Group (IPMG) functions and will be based in New Jersey. Brian joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015. Most recently, he served as Teva’s Executive Vice President and Interim Global Chief Legal Officer. During his tenure, he also led Teva’s global litigation strategy and served as General Counsel for its U.S. Generics business.

Extensive Legal Expertise

Brian brings extensive experience navigating the complex legal and regulatory landscape in the global pharmaceutical industry. He holds a Juris Doctor (J.D.) from Yale Law School and a B.A., summa cum laude, from the University of Pennsylvania. Commenting on the appointment, Lupin CEO Vinita Gupta and Managing Director Nilesh Gupta said, “We are delighted to welcome Brian to our executive leadership team. His deep understanding of the pharmaceutical industry landscape, extensive legal expertise, and proven leadership will be valuable as we continue to strengthen our governance framework, navigate an evolving regulatory environment, and advance our long term growth ambitions.”

Leadership Role

In his new role, Brian will oversee all legal, compliance, and intellectual property functions across Lupin’s global operations. His appointment is expected to further enhance the company’s governance and regulatory compliance framework, ensuring alignment with global best practices and industry standards.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Lupin Limited

Lupin Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Lupin drops 19.7% over three months and trades near its 52-week lows. The PEG of 0.12 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.1% and profits at 131.5% CAGR. That is strong double-digit growth on both counts. The stock sits at 10% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. The business compounds at 19.1% revenue and 131.5% profit CAGR, with D/E of 0.32. Yet the stock drops 19.7% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Lupin Limited.